#United States #New York #oncology #Radiation Therapy #Actinium Pharmaceuticals

Actinium Pharmaceuticals: A Step Forward in Targeted Therapies

Actinium Pharmaceuticals, known for its innovative approach in the field of targeted radiotherapies, has taken a significant step by announcing the formation of a dedicated Scientific Advisory Board. This board is composed of five eminent clinicians and scientists who are recognized globally for their extensive expertise in oncology, nuclear medicine, and radiopharmaceutical development. The establishment of this advisory board is a crucial milestone for Actinium as it pushes the boundaries of clinical development, particularly in the domain of radioconjugates.

The Role of the Scientific Advisory Board

The newly formed Scientific Advisory Board is expected to provide strategic scientific and clinical guidance that will be instrumental in advancing Actinium's differentiated radioconjugate pipeline. Among the key components of this pipeline is ATNM-400, a cutting-edge HER3-targeted alpha radiotherapy which is currently undergoing its first human Phase 1 study aimed at treating metastatic castration-resistant prostate cancer (mCRPC). The collective expertise of the advisory board will play a pivotal role in shaping clinical development strategies, trial designs, patient selection, and therapeutic combinations essential for both solid tumors and hematologic malignancies.

CEO Sandesh Seth expressed optimism regarding this new board, noting that their remarkable professional backgrounds and insights will significantly contribute to optimizing clinical trial designs and accelerating the development of targeted therapies that address unmet medical needs in oncology.

Meet the Experts

The advisory board includes a diverse group of professionals, each bringing a wealth of knowledge that is critical to Actinium's mission:

• - Karim Fizazi, MD, PhD: With a prestigious position as the Director General at the Centre Oscar Lambret in France and a professor of Oncology at Paris-Saclay University, Dr. Fizazi is a preeminent figure in prostate cancer research. His past contributions have shaped the standard treatment protocols for advanced disease, and he has been a champion of collaborative clinical trials across Europe.

• - Sergio A. Giralt, MD: As a Deputy Division Head of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center, Dr. Giralt has been at the forefront of advancing stem cell transplantation, especially for patients who are older or medically vulnerable, thus redefining clinical practices globally.

• - Jason S. Lewis, PhD: A leading radiochemist and innovator, Dr. Lewis specializes in molecular imaging and targeted radiopharmaceuticals. His work focuses on developing cancer-targeting imaging agents, which are essential in translational research within oncology.

• - Michael J. Morris, MD: Renowned for his advancements in prostate cancer treatment, Dr. Morris has contributed to pivotal clinical trials that led to new FDA-approved therapies for mCRPC, illustrating his deep involvement in translating clinical findings into real-world therapeutic applications.

• - Neeta Pandit-Taskar, MD, MBA: Dr. Pandit-Taskar stands at the intersection of nuclear medicine and theranostics. Her insightful work in individualized radiation delivery has garnered her multiple accolades and further solidifies her as a leader in clinical translation research.

Actinium's Vision for the Future

Actinium Pharmaceuticals maintains a clear and ambitious vision: to transform cancer treatment methodologies by developing innovative radioconjugates that maximize therapeutic efficacy while minimizing the toxicity often associated with cancer treatments. Their pipeline reflects a robust strategy focused on three major areas: therapies targeting solid tumors, innovative treatment for acute myeloid leukemia and myelodysplastic syndrome, and advanced conditioning agents for cell and gene therapy.

Through the insights provided by their newly formed Scientific Advisory Board, Actinium aims to prioritize the most promising research avenues and expedite the path to effective therapies. With such an esteemed group guiding their efforts, the company is well-positioned to make substantial advancements that could significantly improve patient outcomes in oncology.